Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Native mass spectrometry (MS) involves the analysis and characterization of
macromolecules, predominantly intact proteins and protein complexes, whereby as much as …

The coronavirus disease (COVID-19) caused by SARS-CoV-2 is creating tremendous
human suffering. To date, no effective drug is available to directly treat the disease. In a …

Small molecule drug discovery has been propelled by the continual development of novel
scientific methodologies to occasion therapeutic advances. Although established …

The main protease of SARS‐CoV‐2 (Mpro), the causative agent of COVID‐19, constitutes a
significant drug target. A new fluorogenic substrate was kinetically compared to an internally …

Since its outbreak in late 2019, the COVID-19 pandemic has drawn enormous attention
worldwide as a consequence of being the most disastrous infectious disease in the past …

The main protease (Mpro) of SARS-CoV-2 is central to viral maturation and is a promising
drug target, but little is known about structural aspects of how it binds to its 11 natural …

Since its onset in December 2019, severe acute respiratory syndrome coronavirus 2, SARS-
CoV-2, has caused over 6.5 million deaths worldwide as of October 2022. Attempts to curb …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a serious threat to
human health and lacks an effective treatment. There is an urgent need for both real-time …

Some medically important viruses―including retroviruses, flaviviruses, coronaviruses, and
herpesviruses―code for a protease, which is indispensable for viral maturation and …